Tempus, a clinical data collection and analytics platform launched in 2015 by Groupon co-founder Eric Lefkofsky, raises $200M Series F at a valuation of $3.1B
Noah Kirsch / Forbes :
Context & Ripple Effects
Eric Lefkofsky's second act after Groupon is now one of the better-capitalized private companies applying AI to medical records: this $200M Series F at $3.1B extends a funding run that would later include a $275M equity-and-debt round in 2022, pushing total funding past $1.3B.
The arc matters because it ends in the public markets — Tempus filed for an IPO disclosing a $266M net loss on $532M of 2023 revenue, then raised $410.7M pricing at $37 a share and closed its Nasdaq debut up 8.8% at roughly a $6.6B market value, roughly double this round's valuation.
First-order effects
- Tempus gains $200M and a $3.1B valuation to scale its clinical data collection and analytics platform across drug discovery, trials, and diagnostics.
- Lefkofsky converts Groupon-founder credibility into a healthcare-data franchise, giving Chicago a flagship AI-health company.
Second-order effects
- Rivals in AI-driven diagnostics and clinical-trial data face a competitor with the balance sheet to aggregate medical records at scale, pressuring them toward their own large raises or consolidation.
- Investors get a pricing benchmark for health-AI platforms — a $3.1B private mark that the 2024 IPO later validated at roughly double.
Third-order effects
- If the pattern holds, AI companies built on proprietary data aggregation follow a template of successive mega-rounds into public listings, with late-stage private capital effectively underwriting the road to IPO.
- Clinical data becomes a contested strategic asset, pushing hospitals and pharma toward exclusive partnerships with whichever platform can fund the widest collection network.
The trend: AI companies monetizing proprietary data troves are following a well-funded private-rounds-to-IPO path, with each successive raise repricing the category before public markets confirm it.